{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-25-115482","form_type":"8-K","ticker":"RPRX","cik":"0001802768","company_name":"Royalty Pharma plc","filed_at":"2025-05-08T23:59:59+00:00","discovered_at":"2026-05-14T18:02:49.776912+00:00","generated_at":"2026-05-22T05:12:54.723210+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Royalty Pharma Q1 Portfolio Receipts $839M (+17% YoY); raises FY2025 guidance","bullets":["Royalty Receipts grew 12% to $788M; cystic fibrosis franchise, Trelegy, Xtandi drove growth.","Raised FY2025 Portfolio Receipts guidance to $2,975M-$3,125M (prior $2,900M-$3,050M).","Repurchased 23M shares for $723M under new $3B buyback program.","Internalization of manager RP Management ($1.1B) vote May 12, closing expected Q2 2025.","Biogen R&D funding for litifilimab (up to $250M); $50M upfront in Q1."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-25-115482","json":"https://secwatch.observer/filing/0001193125-25-115482.json","markdown":"https://secwatch.observer/filing/0001193125-25-115482.md","text":"https://secwatch.observer/filing/0001193125-25-115482.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1802768/000119312525115482/0001193125-25-115482-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1802768/000119312525115482/d938501d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-22T05:12:54.723210+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}